It is with great interest that we read the publication written by Salem et al1: “Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.” This article gave results of the first randomized study comparing 2 different (radio- vs chemo-) embolization approaches, with the primary objective significantly in favor of radioembolization, with a median time to progression (TTP) of 26 months versus 6.5 months after chemoembolization, with a hazard ratio of 0.122 (95% confidence interval, 0.027-0.557; P = .007).